All In Biotech

Drug Trial Radar · NCT00392106

High Intensity Focused Ultrasound (HIFU) Ablation System Study

Study of Focused Circumferential UltraSound for the Treatment of Atrial Fibrillation

Last checked: Nov 20, 2026Latest source record: Jun 17, 2008 (this record)Source: ClinicalTrials.govMethods & limitations

SuspendedPivotal-lookingPhase 3. Randomized with 240 participants. This is a heuristic, not a regulatory label.

Status

Suspended

Enrollment

240

Planned (sponsor's estimate)

Start

Apr 2006

Primary completion

Dec 2010

Study completion Jun 2011

Sponsor

Lead sponsor
ProRhythm, Inc.Industry
Sponsor type
Industry
First posted
Oct 25, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine if the HIFU Pulmonary Vein Ablation System is effective in the treatment of paroxysmal Atrial Fibrillation compared to the control of best medical therapy with FDA approved antiarrhythmic drugs.

Conditions

  • Atrial Fibrillation

Interventions

  • propafenoneDrug

    Anti-arrhythmic drug prescribed for treatment of atrial fibrillation

  • flecainideDrug

    Anti-arrhythmic drug prescribed for the treatment of Atrial fibrillation

  • dofetilideDrug

    Anti-arrhythmic drug prescribed for treatment of atrial fibrillation

  • sotololDrug

    Anti-arrhythmic Drug prescribed for treatment of Atrial Fibrillation

  • Pulmonary vein ablationDevice

    Electrical isolation of pulmonary vein with high-intensity focused ultrasound

  • AmiodaroneDrug

    Anti-arrhythmic Drug prescribed for the treatment of Atrial Fibrillation

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Acute treatment with elimination of AF episodesTime frame: 12 months
  2. Death, stroke, and hospitalization for recurrence of AFTime frame: within 12 months of treatment

Locations

21 sites in 2 countries. Site status is shown where the registry gives one.

  • Fullerton Vascular Medical Group

    Fullerton, California

  • University of California, Los Angeles

    Los Angeles, California

  • Piedmont Hospital

    Atlanta, Georgia

  • Lexington Central Baptist Hospital

    Lexington, Kentucky

  • Johns Hopkins Hopsital

    Baltimore, Maryland

  • Lahey Clinic

    Burlington, Massachusetts

  • Beaumont Hospital

    Royal Oak, Michigan

  • New York University Hospital

    New York, New York

  • Stony Brook University Hospital

    Stony Brook, New York

  • Wake Forest University Health Systems

    Winston-Salem, North Carolina

  • Hillcrest Hospital

    Cleveland, Ohio

  • Cleveland Clinic Foundation

    Cleveland, Ohio

  • The Ohio State University Heart Center

    Columbus, Ohio

  • Oklahoma University Health Sciences Center

    Oklahoma City, Oklahoma

  • Hospital of the University of Pennsylvania

    Philadelphia, Pennsylvania

  • Medical University of South Carolina

    Charleston, South Carolina

  • Texas Cardiac Arrhythmia Research

    Austin, Texas

  • University of Texas, Southwestern

    Dallas, Texas

  • University of Virginia

    Charlottesville, Virginia

  • Sentara Norfolk General Hospital

    Norfolk, Virginia

  • Homolka Hospital

    Prague, Czechia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.